WallStreetZenWallStreetZen

NASDAQ: KALA
Kala Bio Inc Stock

$7.85-0.03 (-0.38%)
Updated Mar 27, 2024
KALA Price
$7.85
Fair Value Price
-$3.41
Market Cap
$21.14M
52 Week Low
$5.10
52 Week High
$19.57
P/E
-0.34x
P/B
1.88x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$46.42M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
4.45
Operating Cash Flow
-$34M
Beta
0.57
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

KALA Overview

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KALA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

KALA ($7.85) is overvalued by 329.96% relative to our estimate of its Fair Value price of -$3.41 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KALA ($7.85) is not significantly undervalued (329.96%) relative to our estimate of its Fair Value price of -$3.41 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KALA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KALA due diligence checks available for Premium users.

Be the first to know about important KALA news, forecast changes, insider trades & much more!

KALA News

Valuation

KALA fair value

Fair Value of KALA stock based on Discounted Cash Flow (DCF)
Price
$7.85
Fair Value
-$3.41
Undervalued by
329.96%
KALA ($7.85) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KALA ($7.85) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KALA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

KALA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.34x
Industry
53.92x
Market
44.45x

KALA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.88x
Industry
2.2x
KALA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

KALA's financial health

Profit margin

Revenue
$0.0
Net Income
-$8.7M
Profit Margin
0%
KALA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$61.1M
Liabilities
$49.9M
Debt to equity
4.45
KALA's short-term assets ($57.90M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KALA's short-term assets ($57.90M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KALA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KALA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.0M
Investing
$9.7M
Financing
$40.0k
KALA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

KALA vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
KALA$21.14M-0.38%-0.34x1.88x
QLI$21.81M+1.67%-2.77x0.51x
TLPH$18.67M-1.79%-0.85x1.32x
TXMD$23.79M0.00%0.30x0.85x
FLGC$18.31M+8.25%-0.23x1.28x

Kala Bio Stock FAQ

What is Kala Bio's quote symbol?

(NASDAQ: KALA) Kala Bio trades on the NASDAQ under the ticker symbol KALA. Kala Bio stock quotes can also be displayed as NASDAQ: KALA.

If you're new to stock investing, here's how to buy Kala Bio stock.

What is the 52 week high and low for Kala Bio (NASDAQ: KALA)?

(NASDAQ: KALA) Kala Bio's 52-week high was $19.57, and its 52-week low was $5.10. It is currently -59.89% from its 52-week high and 53.92% from its 52-week low.

How much is Kala Bio stock worth today?

(NASDAQ: KALA) Kala Bio currently has 2,693,116 outstanding shares. With Kala Bio stock trading at $7.85 per share, the total value of Kala Bio stock (market capitalization) is $21.14M.

Kala Bio stock was originally listed at a price of $924.50 in Jul 20, 2017. If you had invested in Kala Bio stock at $924.50, your return over the last 6 years would have been -99.15%, for an annualized return of -54.83% (not including any dividends or dividend reinvestments).

How much is Kala Bio's stock price per share?

(NASDAQ: KALA) Kala Bio stock price per share is $7.85 today (as of Mar 27, 2024).

What is Kala Bio's Market Cap?

(NASDAQ: KALA) Kala Bio's market cap is $21.14M, as of Mar 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Kala Bio's market cap is calculated by multiplying KALA's current stock price of $7.85 by KALA's total outstanding shares of 2,693,116.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.